• Home
Scientific article
English

Clinical utility of FDG-PET for the clinical diagnosis in MCI

ContributorsArbizu, Javier; Festari, Cristina; Altomare, Daniele; Walker, Zuzana; Bouwman, Femke; Rivolta, Jasmine; Orini, Stefania; Barthel, Henryk; Agosta, Federica; Drzezga, Alexander; Nestor, Peter; Boccardi, Marina; Frisoni, Giovanni; Nobili, Flavio
Published inEuropean Journal of Nuclear Medicine and Molecular Imaging, vol. 45, no. 9, p. 1497-1508
Publication date2018
Abstract

We aim to report the quality of accuracy studies investigating the utility of [18F]fluorodeoxyglucose (FDG)-PET in supporting the diagnosis of prodromal Alzheimer's Disease (AD), frontotemporal lobar degeneration (FTLD) and prodromal dementia with Lewy bodies (DLB) in mild cognitive impairment (MCI) subjects, and the corresponding recommendations made by a panel of experts.

Keywords
  • Alzheimer Disease/diagnostic imaging
  • Cognitive Dysfunction/diagnostic imaging
  • Fluorodeoxyglucose F18
  • Humans
  • Lewy Body Disease/diagnostic imaging
  • Positron-Emission Tomography
Affiliation entities
Research groups
Citation (ISO format)
ARBIZU, Javier et al. Clinical utility of FDG-PET for the clinical diagnosis in MCI. In: European Journal of Nuclear Medicine and Molecular Imaging, 2018, vol. 45, n° 9, p. 1497–1508. doi: 10.1007/s00259-018-4039-7
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal1619-7070
375views
0downloads

Technical informations

Creation04/01/2019 16:25:00
First validation04/01/2019 16:25:00
Update time15/03/2023 15:43:07
Status update15/03/2023 15:43:06
Last indexation02/10/2024 20:44:40
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack